On December 28, Kangmei Pharmaceutical’s evening announcement showed that the listed company had received an investigation order from the Securities and Futures Commission for allegedly breaking the law.
The "Notice of Investigation" of the China Securities Regulatory Commission pointed out: "Because your company is suspected of illegal disclosure of information, according to the relevant provisions of the Securities Law of the People's Republic of China, I will decide to investigate the case against your company, please cooperate."
In this regard, Kangmei Pharmaceutical stated in the announcement that it will fully cooperate with the investigation work of the China Securities Regulatory Commission and fulfill its information disclosure obligations in strict accordance with regulatory requirements.
The data shows that Kangmei Pharmaceutical has dropped 58.39% for the whole year, and has dropped from 22.13 yuan per share at the beginning of the year to 9.21 yuan per share today. The market value has shrunk by more than 50 billion, and there have been several flashes and one during the period. The word is down. On October 16 this year, Kangmei Pharmaceutical fell all the way after the opening, and soon fell to a down limit, but it rose in the last few minutes before the market closed, eventually closing down 5.97%. After that, it continued to stop for three days. On October 22, it finally opened the daily limit, and the turnover of over 7.2 billion yuan became the second place in the A-share turnover list of the day, setting a huge historical record since the company went public.
Sweetness Polydextrose,Functional Food Ingredient,Low Sweetness Polydextrose
Qingdao Bailong Huichuang Bio-tech Co., Ltd. , https://www.sdblcycn.com